



ELSEVIER

# Author Journey CRUI - Elsevier



## Key information for UNIMI Authors

### 1. How do eligibility is determined of the article for the CRUI agreement?

- The acceptance date of the article should be after the start date of the agreement 1 January 2023
- The corresponding author must be affiliated with Unimi at the acceptance date of the article.
- The article must be from an eligible journal (check the list Hybrid Core, Cell Press and Gold OA [here](#) )
- The article must be associated with the eligible article type (check the type of the article [here](#))

### 2. What is the definition of the Corresponding Author for the purpose of the agreement?

- Corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey
- This is the author who makes the publishing choice on behalf of the author group
- Every article has one corresponding author

# Publishing options after acceptance

Review final and final distribution publication using a Microsoft permission model



Corresponding author	[Redacted]
E-mail address	[Redacted]
Journal	International Journal of Pharmaceutics
Article number	121624
Our reference	IJP_121624
PII	S0378-5173(22)00179-X

Welcome [Redacted]

To help us finalize the publication of your article please complete the publishing form(s) below.

**Note:** you will receive a confirmation e-mail after completing each form.

 Information you may need to provide to complete the forms



## Rights and Access

[Complete the rights and access form >](#)

## Help and Support

[How you can share your article](#)



[Author rights information](#)

[A guide to publishing Open Access](#)

**Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options**

**Author clicks on Complete the Rights and Access information form**

## Rights and Access



**Corresponding author selects his/her affiliation details to identify the authors and match them to the CRUI agreement**

**Author has already provided this information at submission; it is prepopulated**

Corresponding author  
E-mail address  
Journal  
Article number  
Our reference  
PII

### Corresponding Author's Organization

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

Organization name\*

University of Milan

**University of Milan**

Milano, IT

**University of Milan Library of Biology**

Milano, IT

**University of Milan Library of Computer Science**

Milano, IT

**University of Milano-Bicocca University Library**

Milano, IT

**University of Milano-Bicocca**

Milano, IT

Save and Continue >



Corresponding author also adds the co-author affiliation details

Were there any co-authors for this article?

Yes

No

### Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial*	Last name*
<input type="text" value="John"/>	<input type="text" value="Head"/>

Organization name\*

Or use recently selected organization

[+ Add another co-author](#)



**Author can add the Funder details. Funder can be the affiliated institution or a different one. In this example it is Milliman**

Remove funder and view available publishing options using a different email permission model

Did the research in this article receive funding?

Yes

No

## Funder Details ⓘ

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our [Support Center](#)

Organization name\*

Milliman Inc



Grant/Contract numbers\*

GT123



+ Add grant/contract number

+ Add another organization

Previous

Save and Continue >

## HYBRID JOURNALS

- In Hybrid Journals, corresponding author sees the Publishing Options based on the affiliation details provided. Gold OA option is followed by Subscription option, and author is informed that agreement covers the APC
- Corresponding Author selects Gold OA
- If the Approval Manager Unimi rejects the CA request in the Elsevier Platform (because not affiliated), it is made clear that CA not UNIMI will receive a full price invoice. For any details APC.bibliotecadigitale@unimi.it

### Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with the **University of Milan**, upon validation, [agreement between CRUI and Elsevier](#) will cover the APC.

I and others can share and reuse my article in the ways described by the user license I select.

#### Article Publishing Charge (APC)

Price

EUR 3,550.00

Institutional Agreement Discount



- 3,550.00

To pay (on validation)



0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,550.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[CRUI and Elsevier Agreement](#)

### Subscription

Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#).

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined [here](#).

## GOLD OA JOURNALS

- In case of Gold OA journals, corresponding author sees only the Gold OA publishing option and he is informed that UNIMI covers the APC
- the Approval Manager Unimi rejects the CA request in the Elsevier Platform (because not affiliated), it is made clear that author not UNIMI will receive a full price invoice

### Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with **University of Milan**, upon validation, my institute will pay the Article Publication charge(APC). I do not have to pay the APC.

I and others can share and reuse my article in the ways described by the user license I select.

#### Article Publishing Charge (APC)

	Price
	EUR 2,780.00
	Institutional Agreement Discount
	- 2,780.00
<hr/>	
	To pay (on validation)
	0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 2,780.00 (ex. VAT).

[University of Milan and Elsevier Agreement](#)

Previous

Save and Continue >

## Rights and Access



- System presents the corresponding author with the CC license options
- CC BY option is pre-selected



## Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

 CC BY 4.0

A license to permit readers to share and adapt your article for any purpose, even commercially.

[Read more about CC BY 4.0](#)

 CC BY-NC-ND 4.0

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

[Read more about CC BY-NC-ND 4.0](#)

[Previous](#)[Save and Continue >](#)



Author selects the rights

How best do you describe your organization? [View all options](#)

Elsevier B.V.

### Select Your Status

- I am the sole author of the manuscript
- I am one author signing on behalf of all co-authors of the manuscript

Please indicate which of the below applies to you:

- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
- I am a US Government employee but some of my co-authors are not
- I am not a US Government employee but some of my co-authors are
- The work was performed by contractors of the US Government under contract number:

Contract Number\* \_\_\_\_\_

- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
- Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
- None of the above

I am signing as an authorized representative and on behalf of my employer

### Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)\* \_\_\_\_\_

E-mail address\* \_\_\_\_\_

Previous

Save and Continue >



## System presents author with the Journal License Publishing Agreement

Elsevier B.V.

Elsevier B.V.

### Your Status

- I am one author signing on behalf of all co-authors of the manuscript

### License of Publishing Rights

I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

### Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

### Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

## Author agrees to the Journal License Publishing Agreement

For further information see the publishing ethics page at <https://www.elsevier.com/about/our-business/policies/publishing-ethics> and the journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions>

### Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of International Federation of Automatic Control ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.

I have read and agree to the terms of the License Agreement.

17 December 2021

T-copyright license-v5/2017

Previous

Accept Agreement >

## Rights and Access



### Once the author clicks on 'Finish':

- Corresponding author and coauthors receive a copy of summary via email
- Article becomes OA on ScienceDirect within 24 hours
- Approval Manager UNIMI will receive a notification for validation within 48 hours who then has 3 weeks to validate the request
- If Approval Manager UNIMI approves the request, the author will receive the full APC coverage
- If the Librarian/admin rejects the request, the author will receive the full price invoice



#### Review Order

Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none"> <li>I am one author signing on behalf of all co-authors of the manuscript</li> </ul> <p>I may share my final published article widely in accordance with the <a href="#">user License</a> that I have selected. Further details on <a href="#">Elsevier Sharing Policy</a> <a href="#">here</a>.</p>

18 November 2022

[Previous](#)

#### Total payment due

Price (excluding taxes)  
EUR 3,550.00

Institutional Agreement Discount  
 - 3,550.00

**To pay (on validation)**  
 **0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[CRUI and Elsevier Agreement](#)

**In case Gold OA journal, the author will see the following text.**

**“If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050 (ex VAT).”**

[Finish >](#)



Thank you

